Group 1 - The core viewpoint of the articles highlights Dongxing Medical's current stock performance, with a closing price of 25.93 yuan, an increase of 1.89%, and a rolling PE ratio of 28.99, marking a new low in 18 days [1] - Dongxing Medical's total market capitalization is reported at 25.97 billion yuan, with the average PE ratio in the medical device industry at 51.42, and the median at 37.44, placing Dongxing Medical at the 65th position in the industry ranking [1][2] - As of June 30, 2025, Dongxing Medical has 11,381 shareholders, a decrease of 123 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] - The latest quarterly report for Q1 2025 shows Dongxing Medical achieved operating revenue of 78.19 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.06 million yuan, down 39.35%, with a gross profit margin of 44.40% [1]

Company Overview - Dongxing Medical closed at 25.43 yuan on July 3, with a 4.22% increase, resulting in a rolling PE ratio of 28.43, the lowest in 13 days, and a total market capitalization of 2.547 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE of 51.48 and a median PE of 36.88 [1] Financial Performance - For Q1 2025, Dongxing Medical reported revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Capital Flow - On July 3, Dongxing Medical experienced a net inflow of 7.9205 million yuan from main funds, although it has seen a total outflow of 9.666 million yuan over the past five days [1] Industry Comparison - The medical device industry has an average PE of 51.48 and a median PE of 36.88, indicating that Dongxing Medical's valuation is significantly lower than the industry average [2]

Group 1 - The core viewpoint of the articles indicates that Dongxing Medical's stock is currently underperforming compared to its industry peers, with a PE ratio of 27.35, significantly lower than the industry average of 49.45 [1][2] - Dongxing Medical's market capitalization stands at 2.45 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company reported a revenue of 78.19 million yuan for Q1 2025, reflecting a year-on-year decline of 14.84%, and a net profit of 12.06 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Group 2 - The medical device industry has an average PE ratio of 49.45 and a median of 35.92, indicating a generally higher valuation compared to Dongxing Medical [2] - The main products of Dongxing Medical include surgical instruments such as endoscopic staplers, open staplers, and electric hydraulic surgical beds [1] - In terms of capital flow, Dongxing Medical experienced a net outflow of 851,900 yuan on June 26, but had a total inflow of 4.25 million yuan over the past five days [1]

Core Viewpoint - The company, Dongxing Medical, is terminating its IPO fundraising project for the Zihang Medical Device Component Intelligent Manufacturing and Expansion Project due to fluctuations in downstream market demand, and is delaying the completion date for the Weike Medical Minimally Invasive Surgical New Product Project to December 31, 2027 [1][2][7]. Summary by Sections IPO Fundraising Projects - Dongxing Medical announced the termination of the Zihang Medical Device Component Intelligent Manufacturing and Expansion Project and the extension of the Weike Medical Minimally Invasive Surgical New Product Project's completion date to December 31, 2027 [2][7]. - The company raised a net amount of 1.003 billion yuan from its IPO, which was allocated to three main projects [2][3]. Investment Progress - As of May 2025, Dongxing Medical has utilized 171 million yuan of the raised funds, achieving an overall investment progress of only 25.9% [3]. - The investment progress for the Zihang project is 24.6%, while the Weike project is at 16.97%, and the Medical Surgical Instrument R&D Center project is at 30.5% [3]. Financial Performance - Dongxing Medical has experienced a continuous decline in its net profit excluding non-recurring items for three consecutive years, with an overall decrease of approximately 35.5% [6][9]. - The company's revenue and net profit figures from 2021 to 2024 show a downward trend, with a slight recovery in 2024 [8][9]. Market Conditions - The decision to terminate the Zihang project is attributed to changes in market conditions, including intensified competition and a decrease in customer order demand [7]. - The company faces challenges from price drops due to volume-based procurement policies, which have pressured its performance [7]. Stock Performance - As of June 25, Dongxing Medical's stock price closed at 24.77 yuan per share, representing a nearly 44% decline from its IPO price of 44.09 yuan [10].

Core Viewpoint - The company has decided to terminate part of its fundraising projects and delay others, based on a careful assessment of the current market conditions and project progress, ensuring that these decisions align with the long-term interests of the company and its shareholders [1][10]. Fundraising Overview - The company raised a net amount of RMB 1,002,572,682.71 through its initial public offering, verified by an accounting firm [1]. - The company has established a management system for the use of raised funds, ensuring that funds are stored in dedicated accounts and used strictly for their intended purposes [2]. Termination of Fundraising Projects - The project "Zihang Medical Device Component Intelligent Manufacturing and Expansion Project" will be terminated, with the total investment amount reduced from RMB 282.84 million to RMB 143.47 million, and the fundraising investment amount decreased from RMB 282.84 million to RMB 135.77 million [3]. - The termination is influenced by changes in market demand and increased competition, leading to a reassessment of the project's viability [6][7]. Reasons for Project Termination - The implementation of centralized procurement policies has created volatility in market demand, affecting the sales cycle and capacity planning for the project [6]. - The existing production capacity is deemed sufficient to meet current demand, and further investment could lead to idle capacity risks [7]. Impact of Project Termination - The termination is expected to enhance the efficiency of fundraising usage and will not adversely affect the company's normal operations or shareholder interests [8]. - The remaining funds from the terminated project will be retained in dedicated accounts for future investment opportunities [8]. Delay of Fundraising Projects - The "Weike Medical Minimally Invasive Surgical New Product Project" will be delayed, with the expected completion date pushed from June 30, 2025, to December 31, 2027 [9]. - The delay is attributed to changes in market conditions and the need for further product development to meet diverse customer needs [9]. Reasons for Project Delay - The company is adapting to market changes and enhancing product features through increased R&D investment, which has necessitated a phased approach to project implementation [9]. - The execution of procurement policies has affected the expected market release timeline for the company's products [9]. Impact of Project Delay - The delay is a strategic decision that does not involve changes to the project’s implementation structure or total investment, ensuring that it aligns with the company's long-term development goals [9][10].

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 部分募投项目终止及部分募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐人"）作为 江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"或"公司"）首 次公开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市 保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求》《深圳证券交易所创业板股票上市规则》及《深圳证券交易 所上市公司自律监管指第 2 号——创业板上市公司规范运作》等相关法律法规、 规范性文件的要求，对东星医疗本次部分募投项目终止及部分募投项目延期的 事项进行了审慎核查，并发表本核查意见，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意江苏东星智慧医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1922 号）同意注册，并经 深圳证券交易所同意，公司首次向社会公众公开发行人民币普通股（A 股） 2,504.3334 万股，每股发行价为人民币 44.09 元，募集资金总额为人民币 1,104,160,596.06 元 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-027 江苏东星智慧医疗科技股份有限公司 关于部分募投项目终止及部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开第四届董事会第十一次会议以及第四届监事会第十次会议，审议通过 了《关于部分募投项目终止的议案》《关于部分募投项目延期的议案》，公司拟 对首次公开发行股票募投项目"孜航医疗器械零部件智能制造及扩产项目"予以 终止。同时，公司根据当前募投项目的实际建设情况、投资进度以及结合吻合器 行业和市场需求发展情况，在保证募集资金投资项目实施主体、实施方式和投资 总额不变的情况下，将募投项目"威克医疗微创外科新产品项目"达到预定可使 用状态日期延期至 2027 年 12 月 31 日。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-028 江苏东星智慧医疗科技股份有限公司 关于召开公司2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年6月23日召 开了第四届董事会第十一次会议，审议通过了《关于提请召开2025年第一次临 时股东大会的议案》，董事会决定于2025年7月10日（星期四）下午2:30在公司 会议室召开2025年第一次临时股东大会。为了进一步保护投资者的合法权益， 方便公司股东行使表决权，本次股东大会将采用现场投票与网络投票相结合的 方式，根据有关规定，现将股东大会的相关事项通知如下： 一、会议召开基本情况 1、股东大会届次：2025年第一次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第十一次会议审议通过了 《关于提请召开2025年第一次临时股东大会的议案》，本次股东大会的召开符 合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和 《公司章程》的规定。 4、 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-026 一、监事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 6 月 23 日 14:00 在公司会议室以现场方式召开。本次会议通 知已于 2025 年 6 月 19 日通过邮件的方式送达全体监事。本次会议由监事会主席 朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会 议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 江苏东星智慧医疗科技股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于部分募投项目终止的议案》 经审议，监事会认为：公司本次终止部分募投项目的事项，是结合募投项目 的投资进度和实际建设情况，经审慎评估后作出的决定，不存在损害公司及股东 利益的情形，不会对公司的正常生产经营产生不利影响，符合公司长期发展规划 和全体股东的利益。本次 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-025 江苏东星智慧医疗科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第十 一次会议于 2025 年 6 月 23 日 8:45 在公司会议室以现场结合通讯的方式召开。 本次会议通知已于 2025 年 6 月 19 日通过邮件的方式送达全体董事。本次会议应 出席董事 7 人，实际出席董事 7 人，其中独立董事沈世娟女士、朱旗先生、上官 俊杰先生以通讯方式出席会议。会议由董事长万世平先生召集并主持，公司监事、 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《公司 法》等有关法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 （一）审议通过《关于部分募投项目终止的议案》 公司对首次公开发行股票募投项目"孜航医疗器械零部件智能制造及扩产项 目"予以终止，上述募投项目终止后，公司将该项目节余募集资金继续留存于其 专户进行管理。 公司保荐人出 ...